– Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell’s BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. – Phase I/IIa clinical efficacy data will be announced in advance of these conferences. (Accesswire — September …
AUSTIN, Texas—8/28/18– SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. William Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. The new Bricell interview can be heard at https://smallcapvoice.com/blog/8-27-18-smallcapvoice-interview-with-briacell-therapeutics-corp-bctxf/. Dr. Williams, BriaCell’s …
• The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. • The hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy. BERKELEY, Calif. and VANCOUVER, British Columbia, …
To listen to the Webinar, please kindly click on the following link: http://cc.readytalk.com/play?id=fvx4z8
BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new developments, including positive Phase IIa safety information, discovery of tumor shrinkage mechanism, and patient …
Initial Research Report (by RB Milestone Group) – BriaCell Therapeutics Corp. June 21, 2018
ASCO 2018: Interview with Dr. Saveri Bhattacharya on the ongoing Ph I/IIa clinical trial with BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer
(Accesswire — June 13, 2018) – BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year’s MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell’s President and CEO will discuss Bria-IMT™, BriaCell’s lead clinical candidate, its potential in …
AUSTIN, Texas—6/13/18– SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. Bill Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. The new Bricell interview can be heard at https://smallcapvoice.com/blog/6-12-18-smallcapvoice-interview-with-briacell-therapeutics-corp-bctxf/. Dr. Bill Williams, …
BERKELEY, Calif. and VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it will publish its clinical findings in the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO’s Annual Meeting, taking place June …